IMRX · Immuneering Corp · Metrics
$4.12
+0.05 (+1.11%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$276.26M
Shares
64.70M
Volume · Oct 5
166.98K
Avg daily vol (3M)
715.19K
IMRX metrics
54 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$4.07
Market cap
$276.26M
Price action
20 metricsPrice change (1W)
-4.7%
Price change (30D)
-14.9%
Price change (3M)
-21.6%
Price change (6M)
-25.3%
Price change (YTD)
-38.1%
Price change (1Y)
-37.7%
Trailing year
Price change (5Y)
-85.9%
52-week high
$8.33
52-week low
$3.92
Change from 52-week high
-51.1%
Change from 52-week low
+3.8%
Annualized volatility
81.3%
Annualized volatility (3M)
51.3%
Beta
1.2
RSI (14D)
33.4
Price vs SMA 50
-12.1%
Price vs SMA 200
-19.0%
Avg volume (3M)
715,193
Relative volume
0.8
Average dollar volume
$3.37M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
64.70M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.4
reciprocal yield 69.0%
FCF yield
-20.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-06-01
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$63.47M
Net income (TTM)
−$57.28M
Trailing 12 months
Diluted EPS (TTM)
$-0.93
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+79.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-30.0%
Return on assets
-28.3%
Debt / equity
—
Current ratio
19.5
EBITDA (TTM)
−$63.15M
Free cash flow (TTM)
−$56.99M
Quick ratio
19.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$41.32M
Total assets
$202.06M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$56.75M
Capital expenditures (TTM)
$238,462
R&D (TTM)
$44.76M
SG&A (TTM)
—
Stock compensation (TTM)
$6.36M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
112
13F filer change QoQ
+17
Institutional ownership
54.4%
Short interest
3 metricsShort interest
24.0%
Latest settlement · 20.6 days to cover
Days to cover
20.6d
Short-squeeze score
70 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—